作者
Thomas O Carpenter, M Keller, D Schwartz, M Mitnick, C Smith, A Ellison, D Carey, F Comite, R Horst, R Travers, FH Glorieux, CM Gundberg, AR Poole, KL Insogna
发表日期
1996/6/1
期刊
The Journal of Clinical Endocrinology & Metabolism
卷号
81
期号
6
页码范围
2381-2388
出版商
Oxford University Press
简介
Therapy for X-linked hypophosphatemia (XLH) only partially corrects skeletal lesions and is often complicated by hyperparathyroidism. 24,25(OH)2 D3 improves skeletal lesions in a murine model of XLH and suppresses PTH secretion in animals. Therefore, we undertook a placebo-controlled trial of 24,25(OH)2 D3 supplementation to standard treatment in patients with XLH to improve bone disease and reduce hyperparathyroid complications. Fifteen subjects with XLH receiving standard treatment [1,25(OH)2 D3 or dihydrotachysterol plus phosphate] were evaluated, supplemented with placebo, and reevaluated one yr later. 24,25(OH)2 D3 supplementation was then begun and studies repeated after another year. Each patient underwent a detailed evaluation of calcium homeostasis over a 24-h period. Rachitic abnormalities were assessed radiographically in children. Adults underwent bone biopsies. 24,25 …
引用总数
学术搜索中的文章
TO Carpenter, M Keller, D Schwartz, M Mitnick, C Smith… - The Journal of Clinical Endocrinology & Metabolism, 1996